ASCO: Vepdegestrant Ups Survival in ER+, HER2− Advanced Breast Cancer With ESR1 Mutations

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 2, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, June 2, 2025 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly longer progression-free survival in patients with ESR1 mutations, according to a study published online May 31 in the New England Journal of Medicine. The research was presented to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Mario Campone, M.D., Ph.D., from the Institut de Cancérologie de l'Ouest Angers-Nantes in Saint-Herblain, France, and colleagues conducted a phase 3, open-label, randomized trial involving patients with ER-positive, HER2-negative advanced breast cancer who had received one previous line of cyclin-dependent kinase 4 and 6 inhibitor therapy plus one line of endocrine therapy. Patients were randomly assigned to receive vepdegestrant at a dose of 200 mg orally once every day of each 28-day cycle or fulvestrant at a dose of 500 mg on day 1 and day 15 of cycle 1 and on day 1 of subsequent cycles (313 and 311 patients, respectively).

The researchers found that median progression-free survival was 5.0 and 2.1 months with vepdegestrant and fulvestrant, respectively, among the 270 patients with ESR1 mutations (hazard ratio, 0.58). Median progression-free survival was 3.8 and 3.6 months with vepdegestrant and fulvestrant, respectively, among all patients. In 23.4 and 17.6 percent of the patients in the vepdegestrant and fulvestrant groups, respectively, adverse events of grade 3 or higher occurred; adverse events leading to discontinuation occurred in 2.9 and 0.7 percent, respectively.

"Additional follow-up is needed to further characterize the long-term efficacy and safety of vepdegestrant in this population," the authors write.

The study was funded by Pfizer, which is developing vepdegestrant.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-03 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords